

Resource Summary Report

Generated by [nidm-terms](#) on Jul 30, 2026

NOD.Cg-Prkdc^{scid}/J

RRID:IMSR_JAX:001303

Type: Organism

Proper Citation

RRID:IMSR_JAX:001303

Organism Information

URL: <https://www.jax.org/strain/001303>

Proper Citation: RRID:IMSR_JAX:001303

Description: Mus musculus with name NOD.Cg-Prkdc^{scid}/J from IMSR.

Species: Mus musculus

Synonyms: NOD SCID. NOD.CB17-Prkdc/J

Notes: gene symbol note: hemolytic complement|protein kinase; DNA activated; catalytic polypeptide; mutant strain: Hc|Prkdc

Affected Gene: hemolytic complement|protein kinase; DNA activated; catalytic polypeptide

Genomic Alteration: deficient|severe combined immunodeficiency

Catalog Number: JAX:001303

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Prkdc^{scid}/J

Record Creation Time: 20250513T053625+0000

Record Last Update: 20260725T044332+0000

Ratings and Alerts

- Used for genotyping by the Human Islet Research Network community. Contact(s): [Peter Buchwald](mailto:Peter.Buchwald@hirnetwork.org) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for NOD.Cg-Prkdc^{scid}/J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 625 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#).

Huang Y, et al. (2026) Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing loss. *Neoplasia* (New York, N.Y.), 71, 101250.

Imori K, et al. (2026) Loss of Brg1 and Pten in Pancreatic Ductal Cells Forms Intraductal Tubulopapillary Neoplasm via the YAP/TAZ Pathway. *Cellular and molecular gastroenterology and hepatology*, 20(2), 101639.

Sugiyama G, et al. (2026) Vascular Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive Hepatocellular Carcinoma After Combination Therapy With Anti-Programmed Death-Ligand 1 and Anti-Vascular Endothelial Growth Factor-A Antibodies. *Gastro hep advances*, 5(1), 100778.

Rosen JC, et al. (2026) Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms. *British journal of cancer*, 134(1), 165.

den Hollander P, et al. (2026) EMT-induced stem cell and mesenchymal programs can be decoupled via cell division and ESRP1-dependent mechanisms. *iScience*, 29(1), 114284.

Trekitkarnmongkol W, et al. (2026) RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. *Nature cell biology*, 28(1), 197.

Ko MW, et al. (2025) Osteoclast-expanded supercharged NK cells perform superior antitumour effector functions. *BMJ oncology*, 4(1), e000676.

Su Z, et al. (2025) Gut-tropic α CD8⁺ T cells contribute to pancreatic β cell destruction in type 1 diabetes. *Frontiers in immunology*, 16, 1623428.

Mima A, et al. (2025) Mechanistic elucidation of human pancreatic acinar development using single-cell transcriptome analysis on a human iPSC differentiation model. *Scientific reports*, 15(1), 4668.

Kondo M, et al. (2025) Preclinical Comparison of [¹¹¹In]In- and [²²⁵Ac]Ac-DOTA-Trastuzumab IgG, F(ab')₂ and Fab for Theranostic SPECT/CT Imaging and α -Particle

Radioimmunotherapy of HER2-Positive Human Breast Cancer. *Molecular pharmaceuticals*, 22(1), 474.

Dai YD, et al. (2025) Identification of conserved T cell epitopes and flanking amino acid mutants of endogenous retrovirus Gag antigen in nonobese diabetic mice. *ImmunoHorizons*, 9(9).

Kang H, et al. (2025) A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma. *The Journal of clinical investigation*, 135(8).

Li L, et al. (2025) A bacterial toxin as a novel anti-cancer drug modulating the tumor-microenvironment. *Cell death & disease*, 16(1), 874.

Kim JE, et al. (2025) Isoxazole-based molecules restore NK cell immune surveillance in hepatocarcinogenesis by targeting TM4SF5 and SLAMF7 linkage. *Signal transduction and targeted therapy*, 10(1), 15.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. *Frontiers in immunology*, 16, 1518787.

Chung DL, et al. (2025) Virus-human chromatin interactions reorganise 3D genome and hijack KDM5B for promoting metastasis in nasopharyngeal carcinoma. *Nature communications*, 16(1), 7149.

Kawaguchi M, et al. (2025) The Role of Tumor-associated Macrophages in Colorectal Peritoneal Metastasis in Mice. *Juntendo medical journal*, 71(3), 187.

Ishibashi A, et al. (2025) HVJ-E links Apolipoprotein d to antitumor effects. *Journal for immunotherapy of cancer*, 13(6).

Kawano S, et al. (2025) Effect of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2- Breast Cancer Preclinical Models. *Cancers*, 17(7).

Tamura T, et al. (2025) Extracellular Vesicles From Prostate Cancer-Corrupted Osteoclasts Drive a Chain Reaction of Inflammatory Osteolysis and Tumour Progression at the Bone Metastatic Site. *Journal of extracellular vesicles*, 14(6), e70091.